WO2013164837A1 - Pharmaceutical formulations of tnf-alpha antibodies - Google Patents
Pharmaceutical formulations of tnf-alpha antibodies Download PDFInfo
- Publication number
- WO2013164837A1 WO2013164837A1 PCT/IN2013/000129 IN2013000129W WO2013164837A1 WO 2013164837 A1 WO2013164837 A1 WO 2013164837A1 IN 2013000129 W IN2013000129 W IN 2013000129W WO 2013164837 A1 WO2013164837 A1 WO 2013164837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- antibody
- buffer
- adalimumab
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21162387.1A EP3912639A1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
US14/383,533 US10093728B2 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of TNF-alpha antibodies |
AU2013255413A AU2013255413C1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of TNF-alpha antibodies |
CA2866692A CA2866692A1 (en) | 2012-03-07 | 2013-03-05 | Formulations which prevent formation of antibody aggregates |
KR1020167023263A KR20160105535A (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical Formulations of TNF-Alpha Antibodies |
MX2014010776A MX363700B (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies. |
SG11201405475UA SG11201405475UA (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
KR1020147026991A KR101730694B1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical Formulations of TNF-Alpha Antibodies |
JP2014560526A JP2015509526A (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulation |
EA201491644A EA201491644A1 (en) | 2012-03-07 | 2013-03-05 | PHARMACEUTICAL COMPOSITIONS |
AP2014007922A AP2014007922A0 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of TNF-alpha antibodies |
NZ629261A NZ629261A (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
EP13742519.5A EP2822591B1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
BR112014021325A BR112014021325A2 (en) | 2012-03-07 | 2013-03-05 | LIQUID PHARMACEUTICAL FORMULATION AND LYOPHILIZED FORMULATION |
EP18162422.2A EP3412310B1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
CN201380012986.8A CN104159614A (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of TNF-alpha antibodies |
ZA2014/06414A ZA201406414B (en) | 2012-03-07 | 2014-09-01 | Pharamaceuticals formulations of tnf-alpha antibodies |
PH12014501988A PH12014501988B1 (en) | 2012-03-07 | 2014-09-05 | Pharmaceutical formulations of tnf-alpha antibodies |
HK15101176.7A HK1200709A1 (en) | 2012-03-07 | 2015-02-04 | Pharmaceutical formulations of tnf-alpha antibodies tnf- |
US16/123,293 US20190071496A1 (en) | 2012-03-07 | 2018-09-06 | Pharmaceutical formulations of tnf-alpha antibodies |
US17/890,866 US20230047111A1 (en) | 2012-03-07 | 2022-08-18 | Pharmaceutical formulations of tnf-alpha antibodies |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN610MU2012 | 2012-03-07 | ||
IN610/MUM/2012 | 2012-03-07 | ||
IN1606MU2012 | 2012-05-30 | ||
IN1606/MUM/2012 | 2012-05-30 | ||
IN3031/MUM/2012 | 2012-10-17 | ||
IN3031MU2012 | 2012-10-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/383,533 A-371-Of-International US10093728B2 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of TNF-alpha antibodies |
US16/123,293 Continuation US20190071496A1 (en) | 2012-03-07 | 2018-09-06 | Pharmaceutical formulations of tnf-alpha antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013164837A1 true WO2013164837A1 (en) | 2013-11-07 |
Family
ID=48901138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000129 WO2013164837A1 (en) | 2012-03-07 | 2013-03-05 | Pharmaceutical formulations of tnf-alpha antibodies |
Country Status (19)
Country | Link |
---|---|
US (3) | US10093728B2 (en) |
EP (3) | EP3412310B1 (en) |
JP (3) | JP2015509526A (en) |
KR (2) | KR101730694B1 (en) |
CN (1) | CN104159614A (en) |
AP (1) | AP2014007922A0 (en) |
AU (1) | AU2013255413C1 (en) |
BR (1) | BR112014021325A2 (en) |
CA (1) | CA2866692A1 (en) |
CL (1) | CL2014002316A1 (en) |
EA (1) | EA201491644A1 (en) |
HK (1) | HK1200709A1 (en) |
MX (2) | MX363700B (en) |
NZ (1) | NZ629261A (en) |
PH (1) | PH12014501988B1 (en) |
SG (2) | SG10201609982PA (en) |
TR (1) | TR201810815T4 (en) |
WO (1) | WO2013164837A1 (en) |
ZA (1) | ZA201406414B (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140086930A1 (en) * | 2002-08-16 | 2014-03-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating tnf-alpha associated disorders |
EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
WO2015090162A1 (en) * | 2013-12-16 | 2015-06-25 | 浙江海正药业股份有限公司 | Pharmaceutical composition comprising adalimumab |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
WO2015151115A1 (en) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
US9193787B2 (en) | 2012-04-20 | 2015-11-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
EP2946767A1 (en) * | 2014-05-23 | 2015-11-25 | Ares Trading S.A. | Liquid pharmaceutical composition |
US9200070B2 (en) | 2013-10-18 | 2015-12-01 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9234033B2 (en) | 2012-09-02 | 2016-01-12 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
US9255143B2 (en) | 2011-04-27 | 2016-02-09 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2016066688A1 (en) * | 2014-10-28 | 2016-05-06 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
US9340612B2 (en) | 2001-03-19 | 2016-05-17 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
WO2016089946A1 (en) * | 2014-12-02 | 2016-06-09 | Biogen Ma Inc. | Methods and compositions for controlling antibody aggregation |
EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2016162819A1 (en) | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
US9499616B2 (en) | 2013-10-18 | 2016-11-22 | Abbvie Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9550826B2 (en) | 2013-11-15 | 2017-01-24 | Abbvie Inc. | Glycoengineered binding protein compositions |
CN106456538A (en) * | 2014-05-23 | 2017-02-22 | 阿雷斯贸易股份有限公司 | Liquid pharmaceutical composition |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
JP2017516847A (en) * | 2014-05-23 | 2017-06-22 | アレス トレーディング ソシエテ アノニム | Liquid pharmaceutical composition |
US9688752B2 (en) | 2013-10-18 | 2017-06-27 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2017117311A1 (en) * | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
US9708399B2 (en) | 2013-03-14 | 2017-07-18 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9708400B2 (en) | 2012-04-20 | 2017-07-18 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2018004260A1 (en) * | 2016-06-30 | 2018-01-04 | (주)셀트리온 | Stable liquid pharmaceutical preparation |
EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
CN110536698A (en) * | 2016-12-30 | 2019-12-03 | 拜奥卡德联合股份公司 | The aqueous pharmaceutical composition of recombinant monoclonal anti-TNF alpha antibodies |
EP3563867A4 (en) * | 2016-12-30 | 2020-12-16 | Joint Stock Company "Biocad" | Aqueous pharmaceutical composition of a recombinant monoclonal antibody to tnf alfa |
US10940185B2 (en) | 2016-12-28 | 2021-03-09 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
US11021543B2 (en) | 2015-06-24 | 2021-06-01 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11236146B2 (en) * | 2016-10-28 | 2022-02-01 | Celltrion Inc. | Stable pharmaceutical formulation |
WO2022111547A1 (en) * | 2020-11-24 | 2022-06-02 | The University Of Hong Kong | Inhaled powder formulations for respiratory delivery of antibodies |
US11534402B2 (en) | 2017-03-06 | 2022-12-27 | Arecor Limited | Liquid pharmaceutical composition |
US11566079B2 (en) | 2015-11-03 | 2023-01-31 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US11713355B2 (en) | 2014-02-28 | 2023-08-01 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201609982PA (en) * | 2012-03-07 | 2017-01-27 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha anitbodies |
UA117466C2 (en) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
JP6738608B2 (en) * | 2016-01-22 | 2020-08-12 | 田中貴金属工業株式会社 | Chromatographic media |
GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
FR3054444A1 (en) * | 2016-07-29 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | ORAL COMPOSITION OF ANTI-TNF ALPHA ANTIBODY |
WO2018063963A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
WO2018131893A1 (en) | 2017-01-11 | 2018-07-19 | ㈜셀트리온 | Stable liquid formula |
BR112019019162A2 (en) * | 2017-03-16 | 2020-04-14 | Lg Chemical Ltd | liquid formulation of an anti-tnf-a antibody and method for preparing the liquid formulation |
CN108686205B (en) * | 2017-04-07 | 2021-12-10 | 海正生物制药有限公司 | Lyophilized preparation of infliximab |
CN108686204A (en) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | Include the infliximab composition of histidine buffer system |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
CA3071930A1 (en) * | 2017-08-08 | 2019-02-14 | Csl Behring Ag | Hemopexin formulations |
CN110151988A (en) * | 2018-02-11 | 2019-08-23 | 百奥泰生物制药股份有限公司 | A kind of human antibody preparation of targeted therapy TNF-α related disease |
CN110302377B (en) * | 2018-02-11 | 2020-04-17 | 百奥泰生物制药股份有限公司 | Human antibody preparation for targeted therapy of TNF- α related diseases |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
US20220042977A1 (en) * | 2020-08-04 | 2022-02-10 | ProStabilis, Inc. | Protein Solubility Screening Kits and Their Use |
KR20230054395A (en) * | 2020-08-20 | 2023-04-24 | 모멘타 파머슈티컬스 인코포레이티드 | sialylated glycoproteins |
AU2022348349A1 (en) * | 2021-09-16 | 2024-05-02 | Aprogen Inc. | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016286A2 (en) * | 2002-08-16 | 2004-02-26 | Abbott Biotechnology Ltd. | Pharmaceutical anti-tnf-alpha antibody formulation |
WO2010077422A2 (en) * | 2008-10-29 | 2010-07-08 | Wyeth Llc | Formulations of single domain antigen binding molecules |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US609382A (en) | 1898-08-16 | Cotton-chopper | ||
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
CN103275221B (en) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | People's antibody in conjunction with human TNF alpha |
EP0852951A1 (en) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
DE60235013D1 (en) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION OF THE IGG ANTIBODY DACLIZUMAB |
JP4583762B2 (en) * | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | Polypeptide preparation |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
EP1988922A4 (en) * | 2006-02-03 | 2010-06-02 | Medimmune Llc | Protein formulations |
EP2043711A4 (en) * | 2006-06-30 | 2017-08-30 | AbbVie Biotechnology Ltd | Automatic injection device |
RU2009141592A (en) * | 2007-04-11 | 2011-05-20 | Алькон Рисерч, Лтд. (Us) | USE OF TNFα INHIBITOR IN COMBINATION WITH ANTIHISTAMINE TREATMENT FOR TREATMENT OF ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS |
PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
CA2742988A1 (en) * | 2008-11-17 | 2010-05-20 | Genentech, Inc. | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
CN102458469B (en) | 2009-05-04 | 2014-12-24 | 艾伯维生物技术有限公司 | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
HRP20220405T1 (en) * | 2010-08-19 | 2022-05-27 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
EP2471554A1 (en) | 2010-12-28 | 2012-07-04 | Hexal AG | Pharmaceutical formulation comprising a biopharmaceutical drug |
GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
SG10201609982PA (en) * | 2012-03-07 | 2017-01-27 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha anitbodies |
EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
ES2784861T3 (en) | 2012-09-07 | 2020-10-01 | Coherus Biosciences Inc | Stable aqueous formulations of adalimumab |
-
2013
- 2013-03-05 SG SG10201609982PA patent/SG10201609982PA/en unknown
- 2013-03-05 EP EP18162422.2A patent/EP3412310B1/en active Active
- 2013-03-05 EA EA201491644A patent/EA201491644A1/en unknown
- 2013-03-05 CA CA2866692A patent/CA2866692A1/en not_active Abandoned
- 2013-03-05 TR TR2018/10815T patent/TR201810815T4/en unknown
- 2013-03-05 AP AP2014007922A patent/AP2014007922A0/en unknown
- 2013-03-05 KR KR1020147026991A patent/KR101730694B1/en active IP Right Grant
- 2013-03-05 NZ NZ629261A patent/NZ629261A/en not_active IP Right Cessation
- 2013-03-05 AU AU2013255413A patent/AU2013255413C1/en not_active Ceased
- 2013-03-05 KR KR1020167023263A patent/KR20160105535A/en not_active Application Discontinuation
- 2013-03-05 US US14/383,533 patent/US10093728B2/en active Active
- 2013-03-05 JP JP2014560526A patent/JP2015509526A/en not_active Withdrawn
- 2013-03-05 SG SG11201405475UA patent/SG11201405475UA/en unknown
- 2013-03-05 WO PCT/IN2013/000129 patent/WO2013164837A1/en active Application Filing
- 2013-03-05 EP EP21162387.1A patent/EP3912639A1/en not_active Ceased
- 2013-03-05 BR BR112014021325A patent/BR112014021325A2/en not_active Application Discontinuation
- 2013-03-05 MX MX2014010776A patent/MX363700B/en unknown
- 2013-03-05 EP EP13742519.5A patent/EP2822591B1/en not_active Revoked
- 2013-03-05 CN CN201380012986.8A patent/CN104159614A/en active Pending
-
2014
- 2014-08-29 CL CL2014002316A patent/CL2014002316A1/en unknown
- 2014-09-01 ZA ZA2014/06414A patent/ZA201406414B/en unknown
- 2014-09-05 PH PH12014501988A patent/PH12014501988B1/en unknown
- 2014-09-08 MX MX2019003716A patent/MX2019003716A/en unknown
-
2015
- 2015-02-04 HK HK15101176.7A patent/HK1200709A1/en unknown
-
2016
- 2016-09-30 JP JP2016193572A patent/JP6416841B2/en active Active
-
2018
- 2018-06-27 JP JP2018122044A patent/JP2018162295A/en active Pending
- 2018-09-06 US US16/123,293 patent/US20190071496A1/en not_active Abandoned
-
2022
- 2022-08-18 US US17/890,866 patent/US20230047111A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016286A2 (en) * | 2002-08-16 | 2004-02-26 | Abbott Biotechnology Ltd. | Pharmaceutical anti-tnf-alpha antibody formulation |
WO2010077422A2 (en) * | 2008-10-29 | 2010-07-08 | Wyeth Llc | Formulations of single domain antigen binding molecules |
Non-Patent Citations (4)
Title |
---|
MAITY HARIPADA ET AL: "Effects of arginine on photostability and thermal stability of IgG1 monoclonal antibodies", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, NL, vol. 10, no. 8, 1 December 2009 (2009-12-01), pages 761 - 766, XP009148288, ISSN: 1389-2010 * |
MARK CORNELL MANNING ET AL: "Stability of Protein Pharmaceuticals: An Update", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 27, no. 4, 9 February 2010 (2010-02-09), pages 544 - 575, XP019793935, ISSN: 1573-904X, DOI: 10.1007/S11095-009-0045-6 * |
ROBERT J FALCONER ET AL: "Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients", JOURNAL OF CHEMICAL TECHNOLOGY & BIOTECHNOLOGY, vol. 86, no. 7, 7 July 2011 (2011-07-07), pages 942 - 948, XP055076799, ISSN: 0268-2575, DOI: 10.1002/jctb.2657 * |
TIM J KAMERZELL ET AL: "Protein excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 63, no. 13, 26 July 2011 (2011-07-26), pages 1118 - 1159, XP028320148, ISSN: 0169-409X, [retrieved on 20110729], DOI: 10.1016/J.ADDR.2011.07.006 * |
Cited By (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9340612B2 (en) | 2001-03-19 | 2016-05-17 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9738714B2 (en) | 2002-08-16 | 2017-08-22 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8795670B2 (en) * | 2002-08-16 | 2014-08-05 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US20140127222A1 (en) * | 2002-08-16 | 2014-05-08 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating tnf-alpha associated disorders |
US9750808B2 (en) | 2002-08-16 | 2017-09-05 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8802101B2 (en) * | 2002-08-16 | 2014-08-12 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8802100B2 (en) * | 2002-08-16 | 2014-08-12 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8802102B2 (en) * | 2002-08-16 | 2014-08-12 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8911741B2 (en) | 2002-08-16 | 2014-12-16 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-alpha associated disorders |
US8916157B2 (en) | 2002-08-16 | 2014-12-23 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8916158B2 (en) | 2002-08-16 | 2014-12-23 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8932591B2 (en) | 2002-08-16 | 2015-01-13 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US8940305B2 (en) | 2002-08-16 | 2015-01-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US20140086929A1 (en) * | 2002-08-16 | 2014-03-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating tnf-alpha associated disorders |
US9327032B2 (en) | 2002-08-16 | 2016-05-03 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9302011B2 (en) | 2002-08-16 | 2016-04-05 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-α associated disorders |
US9732152B2 (en) | 2002-08-16 | 2017-08-15 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9295725B2 (en) | 2002-08-16 | 2016-03-29 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9950066B2 (en) | 2002-08-16 | 2018-04-24 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9289497B2 (en) | 2002-08-16 | 2016-03-22 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US20140086930A1 (en) * | 2002-08-16 | 2014-03-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating tnf-alpha associated disorders |
US9272041B2 (en) | 2002-08-16 | 2016-03-01 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US20140086931A1 (en) * | 2002-08-16 | 2014-03-27 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating tnf-alpha associated disorders |
US9114166B2 (en) | 2002-08-16 | 2015-08-25 | Abbvie Biotechnology Ltd. | Formulation of human antibodies for treating TNF-α associated disorders |
US9220781B2 (en) | 2002-08-16 | 2015-12-29 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9272042B2 (en) | 2002-08-16 | 2016-03-01 | Abbvie Biotechnology Ltd | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9255143B2 (en) | 2011-04-27 | 2016-02-09 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9505834B2 (en) | 2011-04-27 | 2016-11-29 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9365645B1 (en) | 2011-04-27 | 2016-06-14 | Abbvie, Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9193787B2 (en) | 2012-04-20 | 2015-11-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9708400B2 (en) | 2012-04-20 | 2017-07-18 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9957318B2 (en) | 2012-04-20 | 2018-05-01 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9359434B2 (en) | 2012-04-20 | 2016-06-07 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9346879B2 (en) | 2012-04-20 | 2016-05-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9683033B2 (en) | 2012-04-20 | 2017-06-20 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
EP2863951A1 (en) * | 2012-06-12 | 2015-04-29 | Boehringer Ingelheim International GmbH | Pharmaceutical formulation for a therapeutic antibody |
JP2015519382A (en) * | 2012-06-12 | 2015-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical formulations for therapeutic antibodies |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9234033B2 (en) | 2012-09-02 | 2016-01-12 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9290568B2 (en) | 2012-09-02 | 2016-03-22 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9789185B2 (en) | 2012-09-07 | 2017-10-17 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10207000B2 (en) | 2012-09-07 | 2019-02-19 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10799585B2 (en) | 2012-09-07 | 2020-10-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10786566B2 (en) | 2012-09-07 | 2020-09-29 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10780163B2 (en) | 2012-09-07 | 2020-09-22 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10772959B2 (en) | 2012-09-07 | 2020-09-15 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10772960B2 (en) | 2012-09-07 | 2020-09-15 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9782480B2 (en) | 2012-09-07 | 2017-10-10 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10722579B2 (en) | 2012-09-07 | 2020-07-28 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10716854B2 (en) | 2012-09-07 | 2020-07-21 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9346880B2 (en) | 2012-09-07 | 2016-05-24 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10716852B2 (en) | 2012-09-07 | 2020-07-21 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10716853B2 (en) | 2012-09-07 | 2020-07-21 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10688183B2 (en) | 2012-09-07 | 2020-06-23 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9770507B2 (en) | 2012-09-07 | 2017-09-26 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10286071B2 (en) | 2012-09-07 | 2019-05-14 | Coherus Biosciences, Inc. | Syringe containing stable aqueous formulations of adalimumab |
US9340611B2 (en) | 2012-09-07 | 2016-05-17 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9682145B2 (en) | 2012-09-07 | 2017-06-20 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10286072B2 (en) | 2012-09-07 | 2019-05-14 | Coherus Biosciences, Inc. | Methods of manufacturing stable aqueous formulations of adalimumab |
US9782479B2 (en) | 2012-09-07 | 2017-10-10 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10195275B2 (en) | 2012-09-07 | 2019-02-05 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10159733B2 (en) | 2012-09-07 | 2018-12-25 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9707293B2 (en) | 2012-09-07 | 2017-07-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9757454B2 (en) | 2012-09-07 | 2017-09-12 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10159732B2 (en) | 2012-09-07 | 2018-12-25 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9724414B2 (en) | 2012-09-07 | 2017-08-08 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9724415B2 (en) | 2012-09-07 | 2017-08-08 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9731009B2 (en) | 2012-09-07 | 2017-08-15 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9731008B2 (en) | 2012-09-07 | 2017-08-15 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US10155039B2 (en) | 2012-09-07 | 2018-12-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9737600B2 (en) | 2012-09-07 | 2017-08-22 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9382317B2 (en) | 2012-09-07 | 2016-07-05 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9861695B2 (en) | 2012-09-07 | 2018-01-09 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9808525B2 (en) | 2012-09-07 | 2017-11-07 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
US9708399B2 (en) | 2013-03-14 | 2017-07-18 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9200070B2 (en) | 2013-10-18 | 2015-12-01 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9499616B2 (en) | 2013-10-18 | 2016-11-22 | Abbvie Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9522953B2 (en) | 2013-10-18 | 2016-12-20 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9688752B2 (en) | 2013-10-18 | 2017-06-27 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9200069B2 (en) | 2013-10-18 | 2015-12-01 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9550826B2 (en) | 2013-11-15 | 2017-01-24 | Abbvie Inc. | Glycoengineered binding protein compositions |
RU2664736C2 (en) * | 2013-12-16 | 2018-08-22 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд | Pharmaceutical composition containing adalimumab |
WO2015090162A1 (en) * | 2013-12-16 | 2015-06-25 | 浙江海正药业股份有限公司 | Pharmaceutical composition comprising adalimumab |
US11713355B2 (en) | 2014-02-28 | 2023-08-01 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
WO2015151115A1 (en) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
US10688187B2 (en) | 2014-04-02 | 2020-06-23 | Intas Pharmaceuticals Ltd. | Liquid pharmaceutical composition of adalimumab |
US10772961B2 (en) | 2014-05-23 | 2020-09-15 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
CN106456538A (en) * | 2014-05-23 | 2017-02-22 | 阿雷斯贸易股份有限公司 | Liquid pharmaceutical composition |
US11752208B2 (en) | 2014-05-23 | 2023-09-12 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US11752209B2 (en) | 2014-05-23 | 2023-09-12 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
EP3145487B1 (en) | 2014-05-23 | 2018-08-22 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
JP2021107399A (en) * | 2014-05-23 | 2021-07-29 | フレゼニウス カビ ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Liquid pharmaceutical composition |
EP3939566A1 (en) * | 2014-05-23 | 2022-01-19 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
EP3403646B1 (en) | 2014-05-23 | 2022-09-28 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
CN109248315A (en) * | 2014-05-23 | 2019-01-22 | 费森尤斯卡比德国有限公司 | Composition of liquid medicine |
EP3148510B1 (en) | 2014-05-23 | 2018-06-27 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
EP3741358A1 (en) * | 2014-05-23 | 2020-11-25 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
JP2017516848A (en) * | 2014-05-23 | 2017-06-22 | アレス トレーディング ソシエテ アノニム | Liquid pharmaceutical composition |
EP3476386A1 (en) * | 2014-05-23 | 2019-05-01 | Fresenius Kabi Deutschland GmbH | Liquid pharmaceutical composition |
JP2017516847A (en) * | 2014-05-23 | 2017-06-22 | アレス トレーディング ソシエテ アノニム | Liquid pharmaceutical composition |
CN106535935A (en) * | 2014-05-23 | 2017-03-22 | 阿雷斯贸易股份有限公司 | Liquid pharmaceutical composition |
CN111939257A (en) * | 2014-05-23 | 2020-11-17 | 费森尤斯卡比德国有限公司 | Liquid pharmaceutical composition |
US10426832B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US10426833B2 (en) | 2014-05-23 | 2019-10-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US10493152B2 (en) | 2014-05-23 | 2019-12-03 | Fresenius Kabi Deutschland Gmbh | Adalimumab formulations |
US11712471B2 (en) | 2014-05-23 | 2023-08-01 | Fresenius Kabi Deustschland GmbH | Liquid pharmaceutical composition |
AU2020286276B2 (en) * | 2014-05-23 | 2023-06-01 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
EP2946767A1 (en) * | 2014-05-23 | 2015-11-25 | Ares Trading S.A. | Liquid pharmaceutical composition |
JP2020033361A (en) * | 2014-05-23 | 2020-03-05 | フレゼニウス カビ ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Liquid pharmaceutical composition |
JP2022003091A (en) * | 2014-05-23 | 2022-01-11 | フレゼニウス カビ ドイチュラント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Liquid pharmaceutical composition |
US10729769B2 (en) | 2014-05-23 | 2020-08-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US11707524B2 (en) | 2014-05-23 | 2023-07-25 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
WO2015177059A1 (en) * | 2014-05-23 | 2015-11-26 | Ares Trading S.A. | Liquid pharmaceutical composition |
DE202015009619U1 (en) | 2014-10-28 | 2018-08-29 | Richter Gedeon Nyrt. | Pharmaceutical anti-TNFα antibody formulation |
EP3428189A1 (en) | 2014-10-28 | 2019-01-16 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
DE202015009016U1 (en) | 2014-10-28 | 2016-06-24 | Gedeon Nyrt. Richter | Pharmaceutical anti-TNFα antibody formulation |
DE202015009509U9 (en) | 2014-10-28 | 2018-05-30 | Gedeon Nyrt. Richter | Pharmaceutical anti-TNFα antibody formulation |
WO2016066688A1 (en) * | 2014-10-28 | 2016-05-06 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
US20220016244A1 (en) * | 2014-10-28 | 2022-01-20 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
DE202015009509U1 (en) | 2014-10-28 | 2018-01-18 | Gedeon Nyrt. Richter | Pharmaceutical anti-TNFα antibody formulation |
US20170252437A1 (en) * | 2014-10-28 | 2017-09-07 | Richter Gedeon Nyrt. | Pharmaceutical anti-tnf-alpha antibody formulation |
WO2016089946A1 (en) * | 2014-12-02 | 2016-06-09 | Biogen Ma Inc. | Methods and compositions for controlling antibody aggregation |
EP3053573A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2016124588A1 (en) * | 2015-02-06 | 2016-08-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
WO2016162819A1 (en) | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
US11021543B2 (en) | 2015-06-24 | 2021-06-01 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11566079B2 (en) | 2015-11-03 | 2023-01-31 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US11708419B2 (en) | 2015-11-03 | 2023-07-25 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US11732051B2 (en) | 2015-11-03 | 2023-08-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US11708420B2 (en) | 2015-11-03 | 2023-07-25 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
EP3383435A4 (en) * | 2015-11-30 | 2019-07-10 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
US10525137B2 (en) | 2015-12-30 | 2020-01-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
WO2017117311A1 (en) * | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
US20200215195A1 (en) * | 2015-12-30 | 2020-07-09 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
IL259646B2 (en) * | 2015-12-30 | 2023-06-01 | Genentech Inc | Formulations with reduced degradation of polysorbate |
AU2016380988B2 (en) * | 2015-12-30 | 2022-07-21 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
US10933141B2 (en) | 2015-12-30 | 2021-03-02 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
US11576971B2 (en) | 2016-04-20 | 2023-02-14 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
AU2017287743B2 (en) * | 2016-06-30 | 2020-01-30 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
CN109310628A (en) * | 2016-06-30 | 2019-02-05 | 赛特瑞恩股份有限公司 | Stable liquid pharmaceutical formulation |
US11951207B2 (en) | 2016-06-30 | 2024-04-09 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
EP4338752A3 (en) * | 2016-06-30 | 2024-04-03 | Celltrion, Inc. | Stable liquid pharmaceutical preparation |
AU2020201249B2 (en) * | 2016-06-30 | 2021-07-15 | Celltrion, Inc. | Stable liquid pharmaceutical preparation |
WO2018004260A1 (en) * | 2016-06-30 | 2018-01-04 | (주)셀트리온 | Stable liquid pharmaceutical preparation |
IL263630B2 (en) * | 2016-06-30 | 2023-06-01 | Celltrion Inc | Stable liquid pharmaceutical preparation |
AU2017287743C1 (en) * | 2016-06-30 | 2020-10-01 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
US11236146B2 (en) * | 2016-10-28 | 2022-02-01 | Celltrion Inc. | Stable pharmaceutical formulation |
US10940185B2 (en) | 2016-12-28 | 2021-03-09 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
CN110536698A (en) * | 2016-12-30 | 2019-12-03 | 拜奥卡德联合股份公司 | The aqueous pharmaceutical composition of recombinant monoclonal anti-TNF alpha antibodies |
CN110536698B (en) * | 2016-12-30 | 2024-02-13 | 拜奥卡德联合股份公司 | Aqueous pharmaceutical compositions of recombinant monoclonal anti-TNFα antibodies |
EP3563867A4 (en) * | 2016-12-30 | 2020-12-16 | Joint Stock Company "Biocad" | Aqueous pharmaceutical composition of a recombinant monoclonal antibody to tnf alfa |
US11534402B2 (en) | 2017-03-06 | 2022-12-27 | Arecor Limited | Liquid pharmaceutical composition |
WO2018162503A1 (en) * | 2017-03-06 | 2018-09-13 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
US11534403B2 (en) | 2017-03-06 | 2022-12-27 | Arecor Limited | Liquid pharmaceutical composition |
US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
WO2022111547A1 (en) * | 2020-11-24 | 2022-06-02 | The University Of Hong Kong | Inhaled powder formulations for respiratory delivery of antibodies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
US20240058263A1 (en) | Formulations of antibody | |
TWI738632B (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
TWI548424B (en) | Stable liquid formulation of etanercept | |
US20120128687A1 (en) | Novel antibody formulation | |
TW201424748A (en) | High concentration antibody and protein formulations | |
JP7208302B2 (en) | Pharmaceutical composition containing anti-human TSLP receptor antibody | |
JP7089121B2 (en) | Protein solution preparation containing high concentration of anti-VEGF antibody | |
JP6445169B2 (en) | Stable benzyl alcohol-free aqueous solution containing α-type interferon | |
OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
JP2023553106A (en) | Improved lyophilized formulation | |
CN114652825A (en) | Stable antibody preparation, preparation method and application thereof | |
CN117838854A (en) | Stabilizer composition of antibody medicine and pharmaceutical composition | |
TW201825109A (en) | Stable pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2013742519 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13742519 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 234395 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: P935/2014 Country of ref document: AE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201409733 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2014560526 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14383533 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2866692 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/010776 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20147026991 Country of ref document: KR Kind code of ref document: A Ref document number: 2013255413 Country of ref document: AU Date of ref document: 20130305 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201491644 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014021325 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014021325 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140828 |